Shopping Cart
- Remove All
- Your shopping cart is currently empty
ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 mg | Inquiry | Backorder | |
100 mg | Inquiry | Backorder |
Description | ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes. |
In vitro | ATWLPPR Peptide TFA inhibits VEGF165 binding to NRP-1 by 82% at 100 μM [1]. |
In vivo | ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity, reduces oxidative stress, and potentially mitigates early diabetic-related retinal damage by inhibiting the elevation of inflammation-associated proteins (GFAP, VEGF, and ICAM-1) in the retina [2]. |
Molecular Weight | 954 |
Formula | C42H62F3N11O11 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | H2O: 50 mg/mL (52.41 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.